Who's the fairest of them all? Which provincial pharmacare model would best protect Canadians against catastrophic drug costs?


Related Publications

Smolina K, Weymann D, Morgan S, Ross C, Carleton B. Association between regulatory advisories and codeine prescribing to postpartum women. Journal of the American Medical Association. 2015;313(18):1861-2.
Suter E, Misfeldt R, Mallinson S, Wilhelm A, Boakye O, Marchildon G, et al. Comparative Review of the Policy Landscape of Team-based Primary Health Care Service Delivery in Western Canada. Alberta Health Services; 2014.
Laberge M, Pang J, Walker K, Wong ST, Hogg W, Wodchis WP. QUALICOPC (Quality and Costs of Primary Care) Canada: A focus on the aspects of primary care most highly rated by current patients of primary care practices. Ottawa, ON: Canadian Foundation for Healthcare Improvement; 2014.
McGregor MJ, Abu-Laban RB, Ronald L, McGrail KM, Andrusiek D, Baumbusch J, et al. Nursing Home Characteristics Associated with Resident Transfers to Emergency Department. Canadian Journal on Aging. 2012;33(1):38-48.

Publication Topics

Who's the fairest of them all? Which provincial pharmacare model would best protect Canadians against catastrophic drug costs?

Publication TypeJournal Article
Year of Publication2004
AuthorsCoombes ME, Morgan SG, Barer ML, Pagliccia N
JournalHealthcare quarterly (Toronto, Ont.)Healthc.Q.
Pagessuppl 13 - 9
Date Published2004
KeywordsCanada, Catastrophic Illness, Drug Costs, Insurance, Pharmaceutical Services, Models, Organizational, National Health Programs/organization & administration, Policy Making
AbstractBACKGROUND: Public prescription drug plans vary markedly across Canada. To address perceived inequities in coverage across provinces, the February 2003 First Ministers' Accord on Health Care Renewal committed to ensuring that all Canadians have reasonable access to catastrophic drug coverage. A national standard for "reasonable" catastrophic coverage has yet to be formally defined. OBJECTIVE: To compare the private financial burdens from prescription drugs that Canadian households would face if each of the current provincial pharmacare models were adopted as the national standard. METHODS: Through simulation modelling, we computed household private financial burden by applying the cost-sharing rules from provincial drug plans to a nationally representative set of 4,860 household types differing in size, age composition, income and drug expense levels. The proportions of households that would face private out-of-pocket payments exceeding critical, or catastrophic, percentages of household income were calculated. RESULTS: Private financial burden due to prescription drug costs varies considerably across provincial pharmacare models. Comprehensive, tax-financed pharmacare models that limit out-of-pocket expenditures to a given percentage of income, such as those found in British Columbia, Saskatchewan, Manitoba and Ontario, provide the greatest protection against catastrophic prescription drug costs. There appears, however, to be no "gold standard" for an acceptable financial burden to be borne by patients.
Citation Key297